Socio-economic factors associated with cancer stigma among apparently healthy women in two selected municipalities Nepal Authors: Bandana Paneru, Aerona Karmacharya, Soniya Makaju, Diksha Kafle, Lisasha Poudel, Sushmita Mali, Priyanka Timsina, Namuna Shrestha, Dinesh Timalsena, Kalpana Chaudhary, Niroj Bhandari, Prasanna Rai, Sunila Shakya, Donna Spiegelman, Sangini S Sheth, Anne Stangl, McKenna C Eastment, Archana Shrestha, Bimala Panthee, Achyut Raj Pandey, Bimala Panthee, Bimala Panthee, Bimala Panthee Published: 2024 ABSTRACT AbstractIntroductionCancer is the primary cause of death globally, and despite the significant advancements in treatment and survival rates, it is still stigmatized in many parts of the world. However, there is limited public health research on cancer stigma among the general female population in Nepal. Therefore, this study aims to determine the prevalence of cancer stigma and its associated factors in this group.MethodsWe conducted a cross-sectional study among 426 healthy women aged 30 to 60 years who were residents of Dhulikhel and Banepa in central Nepal. We measured cancer stigma using the Cancer Stigma Scale (CASS). CASS measures cancer stigma in six domains (awkwardness, avoidance, severity, personal responsibility, policy opposition, financial discrimination) on a 6-point Likert scale (strongly disagree to agree strongly) with higher mean stigma scores correlating with higher levels of stigma. We utilized Generalized Estimating Equations (GEE) with multivariable linear regression to identify the socio-demographic factors associated with the CASS score.ResultsOverall, the level of cancer stigma was low, with a mean stigma score of 2.6 (0.6), but it was still present among participants. Stigma related to personal responsibility had the highest levels, with a mean score of 3.9 (1.3), followed by severity with a mean score of 3.2 (1.3), and financial discrimination with a mean score of 2.9 (1.6). There was a significant association between the mean CASS score and older age (mean difference in stigma score: 0.11 points; 95% CI: 0.02–0.20) as well as lower education (difference: -0.02 points; 95% CI: -0.03 to -0.003), after adjusting for age, ethnicity, education, marital status, religion, occupation, and parity.ConclusionWhile overall cancer stigma was low, some domains of stigma were higher among women in a suburban area in central Nepal; thus, indicating that cancer stigma persists in this region despite its low overall prevalence. Introduction Cancer is the leading cause of death worldwide, with age-standardized mortality of 100 per 100,000 population in 2020 [1]. The majority of cancer deaths occur in low- and middle-income countries [1]. In Nepal, the age-standardized cancer incidence rate is 80 per 100,000 with a mortality rate of 54 per 100,000 [1]. Despite recent improvements in treatment and survival, cancer is still a stigmatized disease, [2–4] and one of the most feared illnesses [5]. Health-related stigma subjects a person or group to exclusion, rejection, blame, or devaluation due to the anticipation or experience of negative social judgment regarding their health condition, making it a social phenomenon or personal experience [6]. Public stigma may appear in the form of stereotypes, for instance, viewing individuals who have survived cancer as either incapable or contagious. These stereotypes result in behaviors like avoiding interactions with cancer survivors due to a fear of contracting the disease. Discriminatory actions stemming from these biases can lead to withholding job opportunities or rejecting social interactions [7–9]. This public stigma significantly hinders individuals’ willingness to seek health care [6, 10]. Prior research has predominantly examined stigma related to illnesses such as leprosy [11, 12] epilepsy, HIV/AIDS [13, 14] and mental illness [15–17]. Although people often stigmatized cancer, there is a limited exploration of public stigma in healthy general female populations [10]. Examining public stigma related to cancer is crucial for several reasons. First, stigma could dissuade individuals from participating in cancer prevention and screening efforts, resulting in delayed cancer diagnoses and, ultimately, higher mortality rates [10, 18–20]. Second, public health initiatives aimed at educating people about the behavioral factors linked to cancer, including smoking, obesity, and infection with the human papillomavirus, could create stigma by suggesting that cancer is avoidable and depends on individual behavior and choices [21]. Third, stigma can contribute to health disparities, [22–24] particularly among marginalized groups who may already face barriers to accessing healthcare. Few studies have actively investigated cancer-related stigma and associated socio-demographic factors. Qualitative research delving into experienced and internalized stigma among cancer patients reveals that young, single individuals encounter distinct stigma experiences influenced by their age, gender, marital status, socio-economic position, and family living arrangements [25, 26]. A quantitative exploration of stigma in England revealed a higher prevalence of cancer stigma among men and individuals from ethnic minority backgrounds but no associations with age or social status. Notably, these studies utilized only 18 of the 25 CASS available items, potentially resulting in low internal reliability. Moreover, studies have yet to be conducted in low-income countries, notably Nepal. Our team previously conducted two studies on cancer stigma. The first assessed the validity of the Cancer Stigma Scale (CASS) in the Nepalese context, and the second examined the relationship between cancer stigma and cervical cancer screening uptake, finding that women with higher stigma were less likely to participate in screening. To better understand this, it is important to examine the level and distribution of stigma, identify the domains where stigma is most prevalent, and analyze which socio-economic groups are more affected. Therefore, in this study, we aim to determine item-specific, domain-specific, and overall cancer stigma scores, as well as assess the socio-economic factors associated with cancer stigma. Given the limited research on socio-economic influences on cancer stigma, we selected these factors based on a review of prior literature [10, 20]. Our team previously conducted two studies on cancer stigma. The first assessed the validity of the Cancer Stigma Scale (CASS) in the Nepalese context, [27] and the second examined the relationship between cancer stigma and cervical cancer screening uptake, finding that women with higher stigma were less likely to participate in screening [28]. To better understand this, it is important to examine the level and distribution of stigma, identify the domains where stigma is most prevalent, and analyze which socio-economic groups are more affected. Therefore, in this study, we aim to determine item-specific, domain-specific, and overall cancer stigma scores, as well as assess the socio-economic factors associated with cancer stigma. Given the limited research on socio-economic influences on cancer stigma, we selected these factors based on a review of prior literature [10, 20] The novelty of this study lies in its focus on quantitatively measuring cancer stigma within the non-cancer population, a topic that has been sparsely explored in previous research. Additionally, prior studies have not provided detailed assessments of stigma associated with individual items and domains. This information will be valuable in designing targeted stigma reduction interventions by identifying specific areas that need attention. By identifying these factors, we can develop interventions and policies that can help reduce stigma and its adverse effects on individuals and society and ultimately improve the population’s health, where cancer screening and early treatment are lifesaving. Methods Study design and setting We conducted a cross-sectional study in two municipalities of the Kavrepalanchow district of Nepal, Dhulikhel and Banepa, approximately 30 kilometers east of Kathmandu. Dhulikhel is a semi-urban location with a population of 32,162, while Banepa has a population of 55,628. The dominant ethnic group in both municipalities is the Newar, and 70% of the population is literate. The literacy rate among females is around 75% in both municipalities [29]. Study participants Our study population included women aged 30 to 60 years who were residents of Dhulikhel or Banepa. The exclusion criteria were: a) having a hearing impairment, b) having severe mental health conditions so as being not able to provide informed consent, and c) not being a resident of Dhulikhel or Banepa (i.e., visitors to the area). Recruitment We enrolled the initial 426 women out of 1800 who underwent cervical cancer screening organized by Dhulikhel Hospital from May 15 to September 15, 2021. We estimated the sample size based on an expected proportion of cancer stigma among women of 51%,(10) at a 5% significance level, and a margin of error of 5% [30]. Our Research Assistants (RAs) contacted Female Community Health Volunteers (FCHV) and oriented them to the study objective and expectations. These FCHVs have worked in Nepal since the 1980s and play a pivotal role in the Nepali community health workforce, specializing in health education, counseling, outreach, and resource distribution [31]. The FCHVs disseminated information about the study to women in their network and shared the contact details of the interested participants with the research assistants. Subsequently, the research assistants contacted the women by phone, outlining the study’s objectives and explaining their potential role. Women expressing interest were then formally enrolled in the study after verbal informed consent was obtained, ensuring the anonymity and confidentiality of their information. We conducted the study amid the COVID-19 pandemic. Therefore, interviews were conducted over the phone for infection prevention. Kathmandu University Institutional Review Committee ethical board approved the study (KUIRC no: 35/2021). Data collection Trained research assistants conducted telephonic interviews using a structured questionnaire directly entered electronically (Kobo toolbox) [32]. The questionnaire covered socio-demographic factors and cancer stigma. Measures Cancer stigma We used Nepal’s validated CASS tool [27]. The CASS demonstrated satisfactory internal reliability, with a Cronbach’s alpha of 0.88 for the overall scale and ranging from 0.70 to 0.89 for its six components. [27] The CASS consists of 25 items that assess six domains: (a) awkwardness-5 items, which measures how comfortable people feel around someone with cancer; (b) severity-5 items, which evaluates the expected severity of cancer consequences and the likelihood of recovery; (c) avoidance-5 items, which assesses the extent to which people avoid cancer patients and maintain physical distance from them; (d) personal responsibility-4 items, which determines how much a person’s actions contribute to their cancer; (e) policy opposition-3 items, which gauges the perceived responsibility of the government and the public in the care and treatment of cancer patients; and (f) financial discrimination-3 items, which measures the anticipated deprivation of benefits to cancer patients from banking and insurance services. Participants responded using a 6-point Likert scale ranging from ’disagree strongly’ to ’agree strongly.’ We reversed the scores for five specific items, ensuring higher scores reflected more stigma levels (refer to Table 2 for details on the reverse-scored items). The mean score for each domain was then calculated [10, 17]. Table 2CASS mean score in each domain among participants (n = 426).Mean(sd) Awkwardness 2.4 (1.2) I would feel at ease around someone with cancer (R)2.4 (1.7)I would feel comfortable around someone with cancer (R)2.4 (1.7)I would find it difficult being around someone with cancer2.3 (1.7)I would find it hard to talk to someone with cancer2.2 (1.6)I would feel embarrassed discussing cancer with someone who had it2.7 (1.8) Severity 3.2 (1.3) Once you’ve had cancer, you’re never ‘normal’ again3.2 (1.7)Having cancer usually ruins a person’s career3.4 (1.7)Getting cancer means having to mentally prepare oneself for death3.4 (1.7)Cancer usually ruins close personal relationships3.1 (1.7)Cancer devastates the lives of those it touches2.8 (1.7) Avoidance 1.7 (0.9) If a colleague had cancer, I would try to avoid them1.7 (1.2)I would distance myself physically from someone with cancer1.8 (1.4)I would feel irritated by someone with cancer1.3 (0.8)I would feel angered by someone with cancer1.2 (0.7)I would try to avoid a person with cancer2.1 (1.7) Policy Opposition 1.3 (0.6) More government funding should be spent on the care and treatment of those with cancer (R)1.3 (0.8)The needs of people with cancer should be given top priority (R)1.2 (0.5)We have a responsibility to provide the best possible care for people with cancer (R)1.3 (0.6) Personal Responsibility 3.9 (1.3) A person with cancer is liable for their condition4.2 (1.6)A person with cancer is accountable for their condition4.4 (1.5)If a person has cancer, it’s probably their fault3.6 (1.6)A person with cancer is to blame for their condition3.2 (1.6) Financial discrimination 2.9 (1.6) It is acceptable for banks to refuse to make loans to people with cancer2.4 (1.8)Banks should be allowed to refuse mortgage applications for cancer-related reasons2.6 (1.8)It is acceptable for insurance companies to reconsider a policy if someone has cancer3.7 (1.9) Overall stigma 2.6 (0.6) *Stigma score ranges from 1–6. Higher scores indicate a higher sigma level. (R) indicated reversed in scoring. CASS mean score in each domain among participants (n = 426). *Stigma score ranges from 1–6. Higher scores indicate a higher sigma level. (R) indicated reversed in scoring. Socio-demographic variables Socio-demographic variables included age (in years), ethnicity (Brahmin/ Chettri/Thakuri/Sanyasi, Newar, Magar/Tamang/Rai/Limbu, Sherpa/Bhote, Kami/Damai/Sarki/Gaaine/Baadi, Other), education (number of years of formal education completed), religion (Hindu, Buddhist, Christian), occupation (homemaker, farmer, business, unemployed, others) and parity (number of children). We adopted the questions from previously conducted national surveys in Nepal. Responses were self-reported [33, 34]. Data analysis We calculated summary statistics such as frequency and percentage for categorical variables and mean with Standard Deviation (SD) for continuous variables. We estimated cancer stigma scores for six sub-domains and calculated mean scores for each subscale. We checked the assumptions of linearity, independence, normality, and equal variance for linear regression in our analysis. We used a scatterplot of residuals versus predicted values to assess the linearity and equal variance assumptions. To check for normality, we examined a histogram and a normal probability plot of the residuals. We used the GEE model to address clustering (dependence) by ward. Additionally, to detect multicollinearity, we used the variance inflation factors (VIF) method. The mean VIF was around 2.10, indicating that multicollinearity was not problematic. We utilized GEE with multivariable linear regression, exchangeable working correlation, and robust variance to account for the clustering effect of community people on stigma scores, using the ward level as the clustering level. Variables were selected for multivariable regression analysis based on previous literatures [10, 20] and prior knowledge. We reported crude and adjusted differences in stigma scores and their 95% confidence intervals and p-values. For age variables, we presented coefficients in 10-year increments to enhance interpretability, as one-year changes yield small, less meaningful coefficients, while 10-year groupings capture more substantial age-related trends. We conducted all analyses using STATA-13. For age variables, we have have presented coefficients in 10 years difference Results Table 1 presents the socio-demographic characteristics of the participants. The mean age was 42(8) years. Most participants (43%) were Brahmin/Chhetri and Hindus (87.8%). About a third of the participants (31%) had no formal education, and the majority (39.5%) were farmers. The mean number of children was 2.3 (1.0). Table 1Socio-demographic characteristics of the study participants (n = 426).CharacteristicsFrequency (%)Age (in years), Mean(SD)42.3 (8.1)Ethnicity Brahmin/Chettri/Thakuri/Sanyasi184 (43.2) Newar175 (41.1) Magar/Tamang/Rai/Limbu15 (3.5) Sherpa/Bhote27 (6.3) Kami/Damai/Sarki/Gaaine/Baadi25 (5.9)Religion Hindu374 (87.8) Buddhist28 (6.6) Christian24 (5.6)Education No formal education132 (31.0) Primary49 (11.5) Secondary150 (35.2) Above secondary95 (22.3)Occupation Farmer168 (39.5) Home-maker106 (24.9) Business63 (14.8) Unemployed7 (1.6) *Other82 (19.2)Parity (number), Mean (SD)2.3 (1.1)*Other: cleaner, helper, tailor, labor, parlor,and teacherSD: Standard DeviationEducation(years of formal education completed) 0 = No formal education; 1/5 = primary education; 6/10 = secondary education; and 11/max = above secondary Socio-demographic characteristics of the study participants (n = 426). *Other: cleaner, helper, tailor, labor, parlor,and teacher SD: Standard Deviation Education(years of formal education completed) 0 = No formal education; 1/5 = primary education; 6/10 = secondary education; and 11/max = above secondary Table 2 presents the CASS mean score for each stigma domain. The overall mean total CASS score was 2.6 (0.6). Within the six domains, the highest stigma level pertained to personal responsibility, reflecting the belief that patients are accountable for acquiring cancer with a stigma score of 3.9(1.3). Additionally, high stigma levels were observed in the severity domain, indicating that patients may struggle to return to everyday life, adversely affecting their overall life and relationships with a mean stigma score of 3.2 (1.3). Financial discrimination, manifested by the denial of loans and mortgage applications for cancer patients, also exhibited a notable stigma level with a mean stigma score of 2.9 (1.6). Policy opposition showed a low mean stigma score of 1.3 (0.6), suggesting strong government and community support for cancer patient care. Table 3 demonstrates the mean CASS score in each domain for selected variables. With an increase in age, there is an increase in the overall stigma score and in the severity and avoidance domains. In the awkwardness domain, stigma scores are lower among women under 40 years old compared to other groups. The overall cancer stigma score decreases with increasing education levels. Stigma scores among women with non-formal education are higher in all domains (awkwardness, severity, avoidance, and personal responsibility) except for financial discrimination. The overall mean stigma score is highest among the Sherpa and Bhote ethnic groups, particularly in the severity domain. In the personal responsibility domain, the Damai/Sarki/Gaaine/Baadi ethnic group has the highest stigma score. In the financial discrimination domain, the Newar ethnic group has the highest stigma score. Farmers have the highest stigma scores compared to women in other occupations in the overall score and in the severity and personal responsibility domains. Women engaged in business have the highest stigma score in the financial discrimination domain compared to other occupations. The overall stigma score is highest among women who have more than two children. These women also have the highest stigma scores in the awkwardness, severity, avoidance, and financial discrimination domains. In the personal responsibility domain, women with no children have the highest stigma score. The overall stigma score is highest among women who follow Buddhism. These women have the highest stigma scores in the awkwardness, severity, and financial discrimination domains. Table 3CASS mean score in each domain for selected variable (n = 426).CharacteristicsOverall scoreAwkwardnessSeverityAvoidancePolicy OppositionPersonal ResponsibilityFinancial discriminationAge (years)less than 402.4(0.6)2.3(1.3)2.9(1.3)1.5(0.7)1.5(0.7)3.8(1.3)2.7(1.5)40 to 492.6(0.6)2.5(1.3)3.3(1.2)1.7(0.9)1.3(0.6)3.9(1.3)3.3(1.7)50 and above2.7(0.5)2.5(1.2)3.5(1.2)1.9(1.1)1.3(0.5)4.0(1.1)2.9(1.5)EducationNo formal education2.8(0.7)2.6(1.3)3.5(1.3)1.9(1.1)1.4(0.6)4.2(1.2)2.9(1.6)Primary2.6(0.6)2.6(1.2)3.5(1.1)1.7(1.0)1.3(0.4)3.9(1.3)2.7(1.5)Secondary2.5(0.6)2.3(1.3)3.0(1.1)1.5(0.7)1.2(0.5)3.7(1.3)3.0(1.5)Above secondary2.4(0.5)2.3(1.1)2.9(1.2)1.5(0.7)1.3(0.6)3.7(1.2)3.0(1.7)EthnicityBrahmin/Chhetri2.6(0.6)2.4(1.2)3.2(1.3)1.7 (1.0)1.4(0.6)4.0(1.1)2.7(1.5)Damai/Sarki/Gaaine/Baadi2.5(0.5)2.1(1.1)3.2(1.)21.6(0.8)1.3(0.4)4.7(1.2)2.1(1.4)Magar/Tamang/Rai/Limbu2.2(0.6)2.2(1.0)2.5(1.4)1.6(0.7)1.2(0.3)4.2(1.1)1.7(1.1)Newar2.6(0.6)2.5(1.3)3.2(1.2)1.6(0.8)1.3(0.5)3.5(1.4)3.4(1.6)Sherpa/Bhote2.8(0.7)2.5(1.5)3.6 (1.4)1.7(0.9)1.3(0.5)4.5(1.0)2.9(1.8)OccupationBusiness2.6(0.6)2.4(1.4)3.1(1.2)1.5(0.7)1.3(0.5)3.8(1.4)3.2(1.9)Farmer2.7(0.6)2.4(1.3)3.3(1.3)1.7(0.9)1.3(0.6)4.1(1.2)3.0(1.7)Home-maker2.5(0.6)2.3(1.3)3.0(1.3)1.7(0.9)1.3(0.5)3.8(1.3)2.8(1.4)Others2.6(0.7)2.5(1.3)3.0(1.2)1.6(1.0)1.4(0.7)3.7(1.3)2.8(1.4)Unemployed2.6(0.4)2.7(1.0)2.9(1.3)1.4(0.7)1.7(0.8)3.8(1.5)3.1(1.2)ParityZero2.1(0.7)1.9(0.7)2.1(0.7)1.5(0.7)1.0(0.3)4.1(1.4)2.2(1.9)One to two2.6(0.6)2.4(1.3)3.1(1.3)1.6(0.8)1.3(0.6)3.9(1.3)2.9(1.6)More than two2.7(0.6)2.5(1.3)3.4(1.3)1.8(0.7)1.3(0.5)3.9(1.)23.0(1.6)ReligionBuddhist2.8(0.7)2.6(1.4)3.7(1.2)1.7(0.8)1.3(0.5)4.4(1.1)3.2(1.9)Christian2.6(0.7)2.1(1.2)3.1(1.2)1.6(0.9)1.5(0.9)4.8(0.9)2.4(1.7)Hindu2.6(0.6)2.4(1.3)3.2(1.3)1.7(0.9)1.3(0.6)3.8(1.3)3.0(1.6) CASS mean score in each domain for selected variable (n = 426). In the univariable regression model, the mean cancer stigma score showed associations with age, with older women having a higher mean stigma score, education, with more highly educated women having a lower mean stigma score, and occupation, with farmers having higher mean stigma scores compared to business women. However, after adjusting for socio-demographic variables, the mean cancer stigma score was only associated with age and education. There is a positive association between age and cancer stigma score. When comparing two groups with a ten-year age difference, the older group had a higher cancer stigma score of 0.11 units compared to the younger group, after accounting for differences in education, ethnicity, occupation, parity, and religion (95% CI: 0.02–0.20; p-value = 0.01).There was a significant negative association between education and the mean cancer stigma score (p-value<0.001). The mean cancer stigma score was 0.02 units lower with one year more formal education among women (95% CI:-0.03, -0.01). Cancer stigma score was not significantly associated with other socio-demographic variables such as ethnicity(p-value = 0.31), occupation (p-value = 0.49), parity(p-value = 0.98), and religion (p-value = 0.22). (Table 4) Table 4Factors associated with cancer stigma score among participants (n = 426).CharacteristicsUnivariableMultivariableDifference in CASS score (95% CI)p-valueDifference in CASS score (95% CI)p-value*Age (years), Mean (SD)0.20 (0.10, 0.30)0.0020.11 (0.02, 0.20)0.01Education (years of formal education), Mean (SD)0.04 (-0.05, -0.02)<0.001-0.02 (-0.03, -0.01)<0.001Ethnicity Brahmin/ChhetriRef0.670.31 Damai/Sarki/Gaaine/Baadi0.03 (-0.39, 0.40)-0.07 (-0.34, 0.24) Magar/Tamang/Rai/Limbu0.19 (-0.70, 0.37)-0.23 (- 0.49, 0.04) Newar-0.08 (-0.29, 0.12)0.04 (-0.03, 0.12) Sherpa/Bhote0.09 (-0.31, 0.50)0.07 (-0.28, 0.43)Occupation BusinessRef0.530.49 Farmer0.37(0.08, 0.67)0.01 (-0.09, 0.10) Home-maker0.02 (-0.29, 0.33)-0.06 (-0.23, 0.12) Others0.15 (-0.18, 0.48)0.04 (-0.14, 0.23) Unemployed0.59 (-0.20, 1.38)0.07 (-0.27, 0.41)Parity, Mean (SD)0.09 (-0.01, 0.18)0.10 (-0.24, 0.46)0.98Religion BuddhistRef0.040.22 Christian-0.02 (-0.57, 0.63)-0.13 (-0.63, 0.36) Hindu-0.19 (-0.59, 0.19)-0.16 (-0.40, 0.07)CI: Confidence intervalSD: Standard DeviationAdjusting variables- age, education, ethnicity, occupation, parity and religion*Age coefficients presented in 10 years difference Factors associated with cancer stigma score among participants (n = 426). CI: Confidence interval SD: Standard Deviation Adjusting variables- age, education, ethnicity, occupation, parity and religion *Age coefficients presented in 10 years difference Discussion Our study found a low level of general cancer stigma among apparently healthy women in semi-urban Nepal. However, we observed high levels of cancer stigma in the domains of personal responsibility, severity, and financial discrimination. The cancer stigma score was lowest in the policy opposition domain. Cancer stigma scores were high among older individuals and those with lower levels of formal education. In previous studies exploring cancer stigma, consistently low levels of stigma have been reported, though these levels vary across different domains. Similar to our findings, a recent community-based study conducted in India [35] and a hospital-based study in Nepal [36] reported high stigma in the domains of severity, awkwardness, and personal responsibility, with the lowest levels in policy opposition. Additionally, a cross-sectional study conducted in the UK showed higher cancer stigma in the domains of personal responsibility and severity, similar to our study [10]. In contrast to women from the UK, our study population exhibited a higher total mean cancer stigma score across five sub-domains: severity, awkwardness, financial discrimination, personal responsibility, and avoidance. However, our study participants demonstrated a lower mean stigma score in the domain of policy opposition compared to English women, indicating less support for government funding toward cancer care and treatment [10, 17]. The low mean cancer stigma score observed in the policy opposition sub-domain suggests a distinct perspective in our research. Unlike the findings from the English study, [10] Nepali participants did not anticipate receiving substantial support from the government or community for cancer diagnosis and treatment. This difference can be attributed to Nepal and England’s different health financing mechanisms and community structures. In Nepal, out-of-pocket healthcare expenditure is notably high (55%), [37] compared to England (12.5%) [38]. Our study participants may have experienced a greater need for government support for cancer treatment. Even though we didn’t find a specific literature showing that differences in health financing affect stigma scores. It is plausible that high out-of-pocket expenditure leads participants to believe that more government funding should be spent on the care and treatment of those with cancer, resulting in lower stigma scores in policy opposition. Moreover, Nepal’s more cohesive community structure might have inclined our participants to prioritize the shared responsibility of caring for cancer patients within their community. Several studies show that community cohesion and participation reduce stigma [39–41] However, no study has directly linked community cohesion with reducing cancer stigma in policy opposition. These findings emphasize the significance of contextual factors in shaping attitudes and perceptions related to cancer stigma across different settings. The study revealed a significant inverse association between education and cancer stigma among participants. Similar findings were reported in studies conducted in Ireland [42] and China [43] where individuals with lower levels of education had higher cancer stigma scores. These findings imply that the link between education and cancer stigma may exist across different cultural contexts and regions. Those with lower levels of education may have limited access to health literacy and information on health-related matters, potentially leading to misconceptions and misinformation. Our findings suggest a positive association between older age and cancer stigma among women in Nepal, which is in contrast to studies conducted in England, [10] China, [44] and Kenya [20]. This difference might be explained by the comparatively lower exposure to social media platforms. Specifically, 2.2% of Nepali women aged 50 and above use social media [45]. In the UK, media exposure is considerably higher, with 50% of individuals using social media at 50, [46] while in China, 41.5% of social media users are aged above 40 years [47]. Social media might reduce stigma, fostering awareness, empathy, and community support by disseminating accurate information, personal stories, and advocacy efforts [48]. Other mass media sources for information in Nepal include radio and television; however, there is a lack of literature regarding their use among women in Nepal. Another common source of information on cancer and other health issues is Female Community Health Volunteers through their Health Mother Group meetings. Women aged 35 to 45 are more likely to attend these meetings compared to older age groups [49] This highlights the need for targeted educational interventions to improve knowledge and awareness about cancer among older women in Nepal. This is the first quantitative study conducted in Nepal among healthy adult women to identify the factors associated with cancer stigma. A previous qualitative study in Nepal focused on a limited pool of people with cancer, exploring only a few dimensions of stigma [50]. The current research’s strength lies in applying a quantitative approach that introduces objectivity to measure diverse stigma domains among healthy women who have not experienced cancer themselves. In addition, we used CASS, a standardized tool validated in Nepal, to collect our data to estimate the factors associated with cancer stigma [27]. We utilized multivariable linear regression models, adjusting for potential confounders, including age, education, ethnicity, occupation, parity, and religion, which helps to eliminate alternative explanations of our findings. This study has a few limitations. First, response bias is possible due to the interviewer-administered nature of the surveys. Respondents might have downplayed negative emotions in their responses, possibly causing an underreporting of their experiences and, consequently, our stigma score [51]. Second, convenience sampling techniques may introduce selection bias, limiting our findings’ generalizability to the Nepalese female population. Future research with a random sample of women is needed to confirm our findings. Third, the study’s cross-sectional design provides a snapshot of cancer stigma at a specific time. It cannot determine changes in stigma over time. Fourth, this study employed CASS items to evaluate cancer stigma in general. Nevertheless, stigma may vary across different cancer types [52]. Consequently, future research should strive to explore the stigma associated with specific cancer types and their determinants. Conclusion In conclusion, this study found that overall cancer stigma was low, with a mean stigma score of 2.6 (SD = 0.6), indicating its presence among women in a suburban area of central Nepal. Cancer stigma was highest in the domains of personal responsibility, severity, and financial discrimination. Stigma was higher among older women and lower among those with higher education. Since stigma may affect participation in cancer screening, stigma-reduction interventions targeting older and less educated women are recommended. In conclusion, this study found that overall cancer stigma was low, with a mean stigma score of 2.6 (0.6), indicating its presence among women in a suburban area in central Nepal. Stigma may impact engagement in cancer screening efforts, so stigma reduction intervention focusing on older and less educated women is recommended. Supporting information (DOCX) Data collection tool. (DOCX) “Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal”. As a part of the co-submission. (PDF) Data Availability Data are available within the manuscript as a supporting Information files Funding Statement This study was funded by the National Cancer Institute Support Grant (NCI-P30CA016359) and awarded to Spiegelman D. and Shrestha A. References 21 Jun 2024 PONE-D-24-08679Socio-Economic Factors Associated with Cancer Stigma among Apparently Healthy Women in Semi-urban Nepal.PLOS ONE Dear Dr. Paneru, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Aug 05 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Achyut Raj Pandey Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf 2. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager. To do this, go to ‘Update my Information’ (in the upper left-hand corner of the main menu), and click on the Fetch/Validate link next to the ORCID field. This will take you to the ORCID site and allow you to create a new iD or authenticate a pre-existing iD in Editorial Manager. Please see the following video for instructions on linking an ORCID iD to your Editorial Manager account: https://www.youtube.com/watch?v=_xcclfuvtxQ Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: No Reviewer #2: No ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: No Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: Yes ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: No ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: Thank you for providing opportunity to review the paper. Some comments regarding this manuscript are as follows: 1. Title says semi-urban Nepal which miss lead authors because it seems to be carried out in two purposively selected municipalities of Nepal and this result is not generalizable to all semi-urban area as you have mentioned in the limitation section of the manuscript. Methods: 2. Please check if the regression analysis is multivariable or multivariate ? [Helping document: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518362/] 3. Please clarify about the how variables were selected for multivariable regression analysis. 4. Have you performed the diagnostics to test for the assumptions of the linear regression analysis. If yes, please write in details about how you performed the diagnostics. In addition, How was the distribution of the residuals? Have you checked for the multicollinearity ? 5. You have included SD in the results section. Please write its full form in data analysis section and the bottom of the respective tables in which they are used. 6. Consider writing SD in uniform way throughout the manuscript [abstract and text part used ± whereas line 170 and table 1 used mean(SD)] 7. variables like at least one CCS screening can be a confounder. Why it is not adjusted in multivariable regression 8. There are chances of clustering of data, community of people sharing common characteristics. it is better to address the clustering of the data. Results: 9. Line 197 CI can be opened in line 165 consider writing p-value in uniform way throughout the paper [for example: there is different in line 202 and line 198 ] 10. Reference 31 seems to be the first paper linked to this paper. The sample size is 426. Table 1 from published paper(https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0285771) doesn't match with the table 1 of this paper. For example: there were 184 brahmin/chhetri/sanyashi/thakuri but later it is 182. similarly there are slight differences between two papers. I think the analysis has to be redo after correcting the data . 11. Clarify what other occupations or ethnicity includes in methods or at the bottom of the tables. 12. Readers would like to read the crude CASS score for each categories of selected variables along with the overall CASS score Discussion: 13. Line 212 second part to line 217 is confusing. I think you are summarizing the result but abruptly explanation of the domains comes. 14. Line 226 -line 230: You have been comparing CASS score between Nepal and UK and abruptly you are saying that stigma varies across diseases... This is irrelevant in this paragraph. 15. You are comparing with High income countries. It would be better if it is possible to compare with the low and middle income countries. 16. Line 234: What exact difference in health financing and community structure that resulted in low stigma score in policy opposition. Is there any specific study that reported that difference in health financing and community structure affecting stigma score 17. Line 265: multivariate or multivariable?? References 18. Reference 29 is not valid. Need to cite the original source. 19. Reference 41 is to be corrected 20. Reference 28 to be corrected Reviewer #2: While reviewing the paper, I came across two other similar papers published from the same data set by the same authors. (1) Shrestha A, Stangl AL, Paneru B, Poudel L, Karmacharya A, Makaju S, et al. Validation of 361 the Cancer Stigma Scale in Nepalese Women. Asian Pac J Cancer Prev. 2023 Jan 362 1;24(1):207–14. (2) Paneru B, Karmacharya A, Bharati A, Makaju S, Adhikari B, Kafle D, et al. (2023) Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal. PLoS ONE 18(5): e0285771. https://doi.org/10.1371/journal.pone.0285771 The first paper presents the validity of cancer stigma scale in Nepalese context while the second paper measures the prevalence of cancer stigma and its association with cancer screening uptake. This manuscript also measures the prevalence of cancer stigma, and further identify its associated socio-demographic factors. Authors have not cited the second paper which looks very similar to this manuscript. The prevalence of cancer stigma is presented in both papers; the only difference is that the figures are reported in either percentage or mean. The socio-demographic characteristics of the participants (Table 1) are presented in all the three papers which is same and hence redundant. The authors could have mentioned that the findings are reported in previous work and hence avoid redundant information in the manuscript. The authors must provide a sound scientific rationale for the submitted work and clearly reference and discuss the existing literature. The authors need to provide adequate justification for the novelty of their work. Minor comments Abstract background: Mention it as either general population or general female population in Nepal Abstract results: could you present the measurement scale as well? You can present the scale in methods. This will help to understand the mean score in practical terms Abstract conclusion: the sentence is not clear. Better to rephrase as 'While..., some subdomains of stigma were higher among ---in Nepal' Introduction: the year 2020 is redundant (1st paragraph) Introduction: who does the non-patient refer to? A more clarity is required. (3rd paragraph) Introduction: Could you mention the full form of CASS initially? You can abbreviate afterwards (last paragraph) Method: better to present how many items were under each of the six domains (Measures) Results: How was age treated in the linear regression model? could you make it more clear taking readers into attention? Discussion: what is your notion of categorizing higher and lower levels of cancer stigma when you are presenting means of the sub-domain? (1st paragraph) Discussion: what about other mass media platforms? the sources of information regarding cancer may be varied in Nepalese context (5th paragraph) Conclusion: The conclusion that prevalence of cancer is low needs further explanation while referring to the mean scores. Proper use of abbreviation is recommended throughout the paper. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 25 Jul 2024 Jul 19, 2024 Dear Reviewers, Thank you very much for your valuable comments. They were very helpful in improving this manuscript. I have incorporated the suggested changes into the manuscript to the best of my ability. Please find the response to the comments. Reviewer 1 Title 1. Title says semi-urban Nepal which miss lead authors because it seems to be carried out in two purposively selected municipalities of Nepal and this result is not generalizable to all semi-urban area as you have mentioned in the limitation section of the manuscript. Response: Thank you very much for your response. We will revise the title as follow; “Socio-Economic Factors Associated with Cancer Stigma among Apparently Healthy Women in two selected municipalities Nepal Methods 2. Please check if the regression analysis is multivariable or multivariate ? Response: That was an error. Thank you for noticing. We have revised the term multivariate to multivariable. 3. Please clarify how variables were selected for multivariable regression analysis. Response: Variables were selected for multivariable regression analysis based on previous literatures and prior knowledge. We have added this information in the methods section ADD THE INFO 4. Have you performed the diagnostics to test for the assumptions of the linear regression analysis. If yes, please write in details about how you performed the diagnostics. In addition, How was the distribution of the residuals? Have you checked for the multicollinearity ? Response: Yes, we performed the diagnostics for linear regression. We checked for linearity, independence, normality, and equal variances of the residuals; and collinearity We have added this information in the method section as follows. We checked the assumptions of linearity, independence, normality, and equal variance for linear regression in our analysis. We used a scatterplot of residuals versus predicted values to assess the linearity and equal variance assumptions. To check for normality, we examined a histogram and a normal probability plot of the residuals. We used the GEE model to address clustering (dependence) by ward, which has been addressed in the methods. Additionally, to detect multicollinearity, we used the variance inflation factors (VIF) method. The mean VIF was around 2.10, indicating that multicollinearity was not problematic. 5. You have included SD in the results section. Please write its full form in the data analysis section and the bottom of the respective tables in which they are used. Response: Thank you very much for your comments. We have added the full form of SD as Standard Deviation in data analysis section and the bottom of the respective tables 6. Consider writing SD in uniform way throughout the manuscript [abstract and text part used ± whereas line 170 and table 1 used mean(SD)] Response: Thank you very much. We have made mean (SD) in a uniform way throughout the manuscript. 7. variables like at least one CCS screening can be a confounder. Why it is not adjusted in multivariable regression Response: We didn't adjust for screening uptake because it could serve as a mediator in the relationship between independent variables and cancer stigma. For example, for age, older individuals might have higher screening rates due to more frequent healthcare interactions, which could reduce stigma through increased awareness and education. Adjusting for this mediator could lead to over-adjustment bias.[1] 8. There are chances of clustering of data, community of people sharing common characteristics. it is better to address the clustering of the data. Response: Yes, will utilize Generalized Estimating Equations (GEE) with multivariate linear regression, exchangeable working correlation, and robust variance to account for the clustering effect of community people on stigma scores, using the ward level as the clustering level. However, the results from the GEE analysis were similar to those obtained from the multivariable linear regression. The revised table. Response: We have updated this section and summarize the main findings in the first paragraphs as follows: Our study found a low level of general cancer stigma among apparently healthy women in semi-urban Nepal. However, we observed high levels of cancer stigma in the domains of personal responsibility, severity, and financial discrimination. The cancer stigma score was lowest in the policy opposition domain. Cancer stigma scores were higher among older individuals and those with lower levels of formal education. 9. Line 197 CI can be opened in line 165 consider writing p-value in uniform way throughout the paper [for example: there is different in line 202 and line 198 ] Response: Thank you very much for your comments. We will write p-value in a uniform way throughout the paper. 10. Reference 31 seems to be the first paper linked to this paper. The sample size is 426. Table 1 from published paper(https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0285771) doesn't match with the table 1 of this paper. For example: there were 184 brahmin/chhetri/sanyashi/thakuri but later it is 182. similarly there are slight differences between two papers. I think the analysis has to be redo after correcting the data . Response: This was an error. We will rectify this. 11. Clarify what other occupations or ethnicity includes in methods or at the bottom of the tables. Response: We have clarified other occupations at the bottom of the tables. Other occupations include cleaner, helper, tailor, labor, parlor, and teacher. 12. Readers would like to read the crude CASS score for each category of selected variables along with the overall CASS score Response: We have added the crude CASS score for each domain and over all CASS score with the category of the selected variables in Table 3 in revised manuscript. 13. Line 212 second part to line 217 is confusing. I think you are summarizing the result but abruptly explanation of the domains comes. Response: We have updated this section and summarize the main findings in the first paragraphs as follows: Our study found a low level of general cancer stigma among apparently healthy women in semi-urban Nepal. However, we observed high levels of cancer stigma in the domains of personal responsibility, severity, and financial discrimination. The cancer stigma score was lowest in the policy opposition domain. Cancer stigma scores were higher among older individuals and those with lower levels of formal education. 14. Line 226 -line 230: You have been comparing CASS score between Nepal and UK and abruptly you are saying that stigma varies across diseases... This is irrelevant in this paragraph. 15. You are comparing with High income countries. It would be better if it is possible to compare with the low and middle income countries. Response: Thank you very much for your feedback. There are very limited studies on cancer stigma in low- and middle-income countries. We have included literature from India and Nepal in the discussion section. We have revised this paragraph as follows and incorporated the study from Nepal and India . Discussion is revised as follows; In second paragraph In previous studies exploring cancer stigma, consistently low levels of stigma have been reported, though these levels vary across different domains. Similar to our findings, a recent community-based study conducted in India[2] and a hospital-based study in Nepal [3] reported high stigma in the domains of severity, awkwardness, and personal responsibility, with the lowest levels in policy opposition. Additionally, a cross-sectional study conducted in the UK showed higher cancer stigma in the domains of personal responsibility and severity, similar to our study. [4] In contrast to women from the UK, our study population exhibited a higher total mean cancer stigma score across five sub-domains: severity, awkwardness, financial discrimination, personal responsibility, and avoidance. However, our study participants demonstrated a lower mean stigma score in the domain of policy opposition compared to English women, indicating less support for government funding toward cancer care and treatment.[4,5] 16. Line 234: What exact difference in health financing and community structure that resulted in low stigma score in policy opposition. Is there any specific study that reported that difference in health financing and community structure affecting stigma score. Response: We have added the explanation in the discussion section with citation 17. Line 265: multivariate or multivariable?? Response: Has been addressed in number 2. Multivariate is revised to multivariable throughout the paper. References 18. Reference 29 is not valid. Need to cite the original source. Response: revised citation as follow; Ministry of Health and Population. Female Community Health Programme [Internet]. [cited 2024 Jul 11]. Available from:https://mohp.gov.np/program/female-community-health-programme/en 19. Reference 41 is to be corrected Response: Rectified as follow; Acharya U. Nepal Social Media Users Survey 2021. 2022 May; Available from: https://research.butmedia.org/wp-content/uploads/2022/06/SocialMediaSurvey_Nepal_2021_CMR.pdf 20. Reference 28 to be corrected Response: Rectified as follow; Brooks S. Comparing Two Proportions – Sample Size [Internet]. [cited 2022 Jul 31]. Available from: https://select-statistics.co.uk/calculators/sample-size-calculator-two-proportions/ Reviewer 2 While reviewing the paper, I came across two other similar papers published from the same data set by the same authors. (1) Shrestha A, Stangl AL, Paneru B, Poudel L, Karmacharya A, Makaju S, et al. Validation of 361 the Cancer Stigma Scale in Nepalese Women. Asian Pac J Cancer Prev. 2023 Jan 362 1;24(1):207–14. (2) Paneru B, Karmacharya A, Bharati A, Makaju S, Adhikari B, Kafle D, et al. (2023) Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal. PLoS ONE 18(5): e0285771. https:/ The first paper presents the validity of cancer stigma scale in Nepalese context while the second paper measures the prevalence of cancer stigma and its association with cancer screening uptake. This manuscript also measures the prevalence of cancer stigma, and further identify its associated socio-demographic factors. Authors have not cited the second paper which looks very similar to this manuscript. The prevalence of cancer stigma is presented in both papers; the only difference is that the figures are reported in either percentage or mean. The socio-demographic characteristics of the participants (Table 1) are presented in all the three papers which is same and hence redundant. The authors could have mentioned that the findings are reported in previous work and hence avoid redundant information in the manuscript. The authors must provide a sound scientific rationale for the submitted work and clearly reference and discuss the existing literature. The authors need to provide adequate justification for the novelty of their work. Response: Thank you very much for your comments. Our team did two cancer stigma studies in the same study population.The first paper focused on the validity of the tool in the Nepalese setting. The second paper aims to assess the association between cancer stigma and screening uptake, adjusting for other socio-demographic variables. The current paper aims to determine the cancer stigma score for each item, each domain, and the overall score. The novelty of this study lies in its focus on quantitatively measuring cancer stigma within the non-cancer population, a topic that has been sparsely explored in previous research. Additionally, prior studies have not provided detailed assessments of stigma associated with individual items and domains. This information will be valuable in designing targeted stigma reduction interventions by identifying specific areas that need attention. This is added in the introduction section in the revised manuscript. Minor comments Abstract 1. background: Mention it as either general population or general female population in Nepal Response: This is the general female population. We have updated this in our background. 2. results: could you present the measurement scale as well? You can present the scale in methods. This will help to understand the mean score in practical terms Response: Thank You very much for your comments. We have explained briefly about it in the method section. conclusion: the sentence is not clear. Better to rephrase as 'While..., some subdomains of stigma were higher among ---in Nepal' Response: Conclusion is rephrased as follows; While overall cancer stigma was low, some domains of stigma were higher among women in a suburban area in central Nepal; thus, indicating that cancer stigma persists in this region despite its low overall prevalence. Introduction: the year 2020 is redundant (1st paragraph) Response: Revised 1st paragraph removing 2020 repeatedly. who does the non-patient refer to? A more clarity is required. (3rd paragraph) Response: Revised third paragraph as follows;Although people often stigmatized cancer, there is a limited exploration of public stigma in healthy general female populations. Revise first paragraph as follows; Cancer is the leading cause of death worldwide, with age-standardized mortality of 100 per 100,000 population in 2020.[9] The majority of cancer deaths occur in low- and middle-income countries.[9] In Nepal, the age-standardized cancer incidence rate is 80 per 100,000 with a mortality rate of 54 per 100,000.[9] Despite recent improvements in treatment and survival, cancer is still a stigmatized disease,[10–12] and one of the most feared illnesses.[13] Introduction: Could you mention the full form of CASS initially? You can abbreviate afterwards (last paragraph) Response: Thank You very much for your comments. We have now provided the full form of CASS initially as Cancer Stigma Scale and abbreviated afterwards. Method: better to present how many items were under each of the six domains (Measures) Response: Thank You very much. We will add the number of items under six domains in the method section. Revised measures as follows; The CASS consists of 25 items that assess six domains: (a) awkwardness-5 items, which measures how comfortable people feel around someone with cancer; (b) severity-5 items, which evaluates the expected severity of cancer consequences and the likelihood of recovery; (c) avoidance-5 items, which assesses the extent to which people avoid cancer patients and maintain physical distance from them; (d) personal responsibility-4 items, which determines how much a person's actions contribute to their cancer; (e) policy opposition-3 items, which gauges the perceived responsibility of the government and the public in the care and treatment of cancer patients; and (f) financial discrimination-3 items, which measures the anticipated deprivation of benefits to cancer patients from banking and insurance services Results: How was age treated in the linear regression model? could you make it more clear by taking readers' attention? Response: Age was treated as a continuous variable in the regression model. We have revised the interpretation as follows to make it more clear. There is a positive association between age and cancer stigma score. When comparing two groups with a ten-year age difference, the older group had a higher cancer stigma score of 0.18 units compared to the younger group, after accounting for differences in education, ethnicity, occupation, number of children, and religion (95% CI: 0.04-0.20; p-value=0.04). Discussion: what is your notion of categorizing higher and lower levels of cancer stigma when you are presenting means of the sub-domain? (1st paragraph) Response: We have revised the term higher as high and lower as low in 1st paragraph of discussion Discussion: what about other mass media platforms? the sources of information regarding cancer may be varied in Nepalese context (5th paragraph) Response: We have now Added other platforms as well in the fifth paragraph as follows; Other m Submitted filename: Response to Reviewers.docx 12 Nov 2024 PONE-D-24-08679R1Socio-Economic Factors Associated with Cancer Stigma among Apparently Healthy Women in two selected municipalities of Nepal.PLOS ONE Dear Dr. Paneru, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Most of the comments are addressed satisfactorily However, In the introduction section, justification of the need of the study should be adequately explained as commented by reviewer 2. For instance, what were the findings related to cancer stigma in your previous work and what would you add in your current research? Please add in the introduction section to justify. In addition, on which basis the authors had chosen the factors (socio-economic) associated with stigma among the many factors? As this study aims to find out the factors associated with stigma it is important to justify the selected variables. However, In the introduction section, justification of the need of the study should be adequately explained as commented by reviewer 2. For instance, what were the findings related to cancer stigma in your previous work and what would you add in your current research? Please add in the introduction section to justify. In addition, on which basis the authors had chosen the factors (socio-economic) associated with stigma among the many factors? As this study aims to find out the factors associated with stigma it is important to justify the selected variables. Line 96-100 needs to rewrite/rephrase to make it more clearer and academic Line 96-100 needs to rewrite/rephrase to make it more clearer and academic Could you make it more clearer again about table 3 regarding age? What do you mean by 10 years difference? It is suggested that you mention details in the data analysis section. Could you make it more clearer again about table 3 regarding age? What do you mean by 10 years difference? It is suggested that you mention details in the data analysis section. Conclusion should be made in a separate section and it should reflect the title and aim of your study. Consider rewriting the conclusion section. Conclusion should be made in a separate section and it should reflect the title and aim of your study. Consider rewriting the conclusion section. Please submit your revised manuscript by Dec 27 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript: A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Bimala Panthee Academic Editor PLOS ONE [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #1: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: (No Response) ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: I Don't Know ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: (No Response) ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 13 Nov 2024 Dear Reviewers, Thank you very much for your valuable comments. They were very helpful in improving this manuscript. I have incorporated the suggested changes into the manuscript to the best of my ability. Please find the response to the comments. 1.However, In the introduction section, justification of the need of the study should be adequately explained as commented by reviewer 2. For instance, what were the findings related to cancer stigma in your previous work and what would you add in your current research? Please add in the introduction section to justify. In addition, on which basis the authors had chosen the factors (socio-economic) associated with stigma among the many factors? As this study aims to find out the factors associated with stigma it is important to justify the selected variables. Response: We will add an introduction section as follows. Our team previously conducted two studies on cancer stigma. The first assessed the validity of the Cancer Stigma Scale (CASS) in the Nepalese context, and the second examined the relationship between cancer stigma and cervical cancer screening uptake, finding that women with higher stigma were less likely to participate in screening. To better understand this, it is important to examine the level and distribution of stigma, identify the domains where stigma is most prevalent, and analyze which socio-economic groups are more affected. Therefore, in this study, we aim to determine item-specific, domain-specific, and overall cancer stigma scores, as well as assess the socio-economic factors associated with cancer stigma. Given the limited research on socio-economic influences on cancer stigma, we selected these factors based on a review of prior literature and our professional judgment. 2.Line 96-100 needs to rewrite/rephrase to make it clearer and more academic Response: We will revise it as follows. Our team previously conducted two studies on cancer stigma. The first assessed the validity of the Cancer Stigma Scale (CASS) in the Nepalese context, and the second examined the relationship between cancer stigma and cervical cancer screening uptake. In this study, we aim to determine item-specific, domain-specific, and overall cancer stigma scores, as well as assess the socio-economic factors associated with cancer stigma. Note: In the revised manuscript it is incorporated with comment 1. 3.Could you make it more clearer again about table 3 regarding age? What do you mean by 10 years difference? It is suggested that you mention details in the data analysis section. Response: Thank you very much for your feedback. We will add it as data analysis as follows. For age variables, we presented coefficients in 10-year increments to enhance interpretability, as one-year changes yield small, less meaningful coefficients, while 10-year groupings capture more substantial age-related trends. 4.Conclusion should be made in a separate section and it should reflect the title and aim of your study. Consider rewriting the conclusion section. Response: We will separate conclusion and revise it as follows. Conclusion: In conclusion, this study found that overall cancer stigma was low, with a mean stigma score of 2.6 (SD = 0.6), indicating its presence among women in a suburban area of central Nepal. Cancer stigma was highest in the domains of personal responsibility, severity, and financial discrimination. Stigma was higher among older women and lower among those with higher education. Since stigma may affect participation in cancer screening, stigma-reduction interventions targeting older and less educated women are recommended. Submitted filename: Response to Reviewers-2 .docx 20 Nov 2024 Socio-Economic Factors Associated with Cancer Stigma among Apparently Healthy Women in two selected municipalities of Nepal. PONE-D-24-08679R2 Dear Dr. Paneru, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice will be generated when your article is formally accepted. Please note, if your institution has a publishing partnership with PLOS and your article meets the relevant criteria, all or part of your publication costs will be covered. Please make sure your user information is up-to-date by logging into Editorial Manager at Editorial Manager® and clicking the ‘Update My Information' link at the top of the page. If you have any questions relating to publication charges, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Bimala Panthee Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: 4 Dec 2024 PONE-D-24-08679R2 PLOS ONE Dear Dr. Paneru, I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now being handed over to our production team. At this stage, our production department will prepare your paper for publication. This includes ensuring the following: * All references, tables, and figures are properly cited * All relevant supporting information is included in the manuscript submission, * There are no issues that prevent the paper from being properly typeset If revisions are needed, the production department will contact you directly to resolve them. If no revisions are needed, you will receive an email when the publication date has been set. At this time, we do not offer pre-publication proofs to authors during production of the accepted work. Please keep in mind that we are working through a large volume of accepted articles, so please give us a few weeks to review your paper and let you know the next and final steps. Lastly, if your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Bimala Panthee Academic Editor PLOS ONE Supplementary Materials (DOCX) Data collection tool. (DOCX) “Association between cancer stigma and cervical cancer screening uptake among women of Dhulikhel and Banepa, Nepal”. As a part of the co-submission. (PDF) Submitted filename: Response to Reviewers.docx Submitted filename: Response to Reviewers-2 .docx Data Availability Statement Data are available within the manuscript as a supporting Information files